[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100630043":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":11,"centralContacts":11,"locations":11,"responsibleParty":28,"collaborators":11,"id":30,"slug":31,"hasResults":32,"nctId":33,"briefTitle":34,"officialTitle":35,"acronym":11,"eligibilityCriteria":36,"healthyVolunteers":32,"sex":37,"minAge":38,"maxAge":11,"enrollmentInfo":39,"targetDuration":11,"studyType":42,"phases":43,"briefSummary":45,"conditions":46,"keywords":11,"overallStatus":49,"whyStopped":11,"lastUpdateSubmitDate":50,"lastUpdatePostDateStruct":51,"startDateStruct":54,"completionDateStruct":56,"leadSponsor":58,"locationsCount":11},{"fullName":5,"class":6},"Ain Shams University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Dexmedetomidine","ACTIVE_COMPARATOR",null,[13],"Drug: Dexmedetomidine",{"label":15,"type":16,"description":11,"interventionNames":17},"Placebo","PLACEBO_COMPARATOR",[18],"Other: Saline",[20,24],{"type":21,"name":9,"description":22,"armGroupLabels":23,"otherNames":11},"DRUG","Drug infusion to reduce postoperative atrial fibrillation",[9],{"type":6,"name":25,"description":26,"armGroupLabels":27,"otherNames":11},"Saline","Normal saline infusion for placebo",[15],{"type":29,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100630043","role-of-dexmedatomidine-drug-in-prevention-of-atrial-fibrillations-post-mitral-valve-surgery-100630043",false,"NCT07482540","Role of Dexmedatomidine Drug in Prevention of Atrial Fibrillations Post Mitral Valve Surgery","The Prophylactic Role of Dexmedetomidine Drug in Reducing Early Postoperative New Onset Atrial Fibrillation After Mitral Valve Surgery - a Randomized Controlled Clinical Trial","Inclusion Criteria:\n\nAdult patients aged 21 years or older. American Society of Anesthesiologists (ASA) physical status II-III. Patients able to provide written informed consent.\n\nExclusion Criteria:\n\nHistory of cardiac arrhythmias: atrial fibrillation or any other clinically significant cardiac tachyarrhythmias.\n\nAny degree of atrioventricular block or presence of permanent pacemaker and bradycardia (heart rate \\\u003C 60 beats\u002Fmin) or hemodynamic instability.\n\nEmergency mitral valve surgery. Left ventricular dysfunction (ejection fraction \\\u003C 55%) Ischemic heart disease patients. Severe hepatic or renal impairment. Known hypersensitivity or contraindication to dexmedetomidine. Chronic use of class I or class III anti-arrhythmic drugs","ALL","21 Years",{"count":40,"type":41},140,"ESTIMATED","INTERVENTIONAL",[44],"NA","Recently, dexmedetomidine has been suggested as an alternative agent for sedation in tachyarrhythmias due to its antiarrhythmic properties through decreased catecholamine release, prolonged refractory period, and increased vagal tone. In addition, dexmedetomidine is a highly selective agonist that does not interact with the gamma-aminobutyric acid (GABA) receptors. Thus, its analgesic properties are opioid sparing, which is unique among traditional ICU sedatives and avoids the issue of respiratory depression with over-sedation.\n\nOur aim: To evaluate the potential prophylactic effect of perioperative dexmedetomidine in reducing the incidence of early postoperative new onset atrial fibrillation following mitral valve surgery.",[47,48],"New Onset","Atrial Fibrillation","NOT_YET_RECRUITING","2026-03-14",{"date":52,"type":53},"2026-03-19","ACTUAL",{"date":55,"type":41},"2026-06-01",{"date":57,"type":41},"2027-12-31",{"name":5,"class":6}]